JAIDS Journal of Acquired Immune Deficiency Syndromes:
Infection With Different HIV Subtypes Is Associated With CD4 Activation-Associated Dysfunction and Apoptosis
Bousheri, Stephanie*; Burke, Candace*; Ssewanyana, Isaac†; Harrigan, Richard‡; Martin, Jeffrey§; Hunt, Peter§; Bangsberg, David R∥; Cao, Huyen*
From the *California Department of Health Services, Richmond, CA; †Joint Clinical Research Centre, Kampala, Uganda; ‡British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada; §University of California, San Francisco, CA; and ∥Partners AIDS Research Center, Boston, MA.
Received for publication June 26, 2009; accepted September 18, 2009.
Supported by National Institute of Health grants AI43885 and MH54907.
S. Bousheri and C. Burke contributed equally to this work.
Authors have no commercial or other association that might pose a conflict of interest.
Correspondence to: Dr. Huyen Cao, MD, California Department of Health Services, 850 Marina Bay Parkway, VRDL, Richmond, CA 94804 (e-mail: firstname.lastname@example.org).
Determination of HIV-1 subtype may be important in the management of HIV-infected individuals, particularly with regard to deciding the CD4 cell count at which to initiate antiretroviral therapy. Non-B subtypes, A and D, are prevalent in Uganda, and individuals infected with subtype D seem to have faster disease progression compared with those infected with subtype A. We examined the level of apoptosis in CD4+ T cells in a study cohort of volunteers infected with subtypes A and D infection. Although the levels of apoptosis in the activated CD4+ cells significantly decreased with viral suppression, CD4+ apoptosis in individuals infected with subtype D were found to be significantly higher compared with those infected with subtype A before antiretroviral treatment. Surface expression of PD-1 on CD4 cells in subtype D was substantially higher compared with that in subtype A (P = 0.03). This difference was not observed in the CD8 population (P > 0.05). Our findings suggest that the infecting HIV subtypes exert an independent influence on the disease outcome in response to antiretroviral treatment.
Differences in the genetic characteristics of HIV likely influence the rate of disease progression and the response to antiretroviral therapy (ART). One important unanswered question is the biological basis for the apparent higher virulence of HIV subtype D compared with subtype A.1-6 Surprisingly, knowledge in this area is limited, and no conclusive recommendations currently exist regarding subtype and treatment guidelines or therapeutic monitoring. The level of viral replication and its subsequent effect on the immune system influences CD4+ T-cell depletion. During chronic HIV infection, more CD4+ T cells die than can be accounted for by direct infection.7 This bystander loss of uninfected T cells is believed to be associated with the generalized HIV-induced immune activation.8 We have previously reported higher T-cell activation in Uganda compared with Western cohorts (HIV subtype B).9 We hypothesize that the infecting HIV subtypes exert independent influence on the outcome of immunity in response to antiretroviral treatment in our study population.
MATERIALS AND METHODS
Study Subjects and Samples
HIV-positive ART-naive volunteers were randomly recruited from a prospective observational cohort study from individuals receiving care at the Mbarara Hospital Uganda AIDS Rural Treatment Outcomes in Mbarara, Uganda.10 Demographic information, CD4+ T-cell count, and HIV viral load were obtained at the time of enrollment, and then again at 3 and 6 months after initiation of ART. All patients initiated ART within 2 weeks of being enrolled into the study. HIV-1 RNA levels were determined from plasma using the Roche Amplicor 1.5 (Roche, Branchburg, NJ), as per manufacturer's recommendations. Peripheral blood mononuclear cells (PBMCs) were obtained from enrolled volunteers. PBMC samples were isolated from whole blood by the use of density gradient centrifugation over ficoll-hypaque solution, cryopreserved immediately, and stored in liquid nitrogen. Institutional Review Board approvals were obtained from the Uganda National Council of Sciences and Technologies, the UCSF committee on Human Research, and the California Department of Public Health. All study patients participated voluntarily and gave written informed consent.
Subtyping was based on plasma sequencing for Pol as previously reported.11 Briefly, RNA was extracted from plasma using the Qiagen viral RNA kit with a BioRobot 9600/9604. HIV Pol genes were amplified using nested reverse transcriptase polymerase chain reaction and sequenced in both the 5′ and 3′ directions. The National Institutes of Health's HIV-1 Genotyping Tool Web site (http://www.ncbi.nlm.nih.gov/projects/genotyping/formpage.html) in conjunction with the Los Alamos HIV sequence database (http://www.hiv.lanl.gov/content/sequence/HIV/mainpage.html) was used to determine the HIV-1 subtype.
HIV-1 infection-induced cleavage of procaspases results in cell apoptosis. Flow cytometry analysis approach allows for the detection of apoptotic cells at the single cell level. We measured caspase activity by using the Vybrant FAM Poly Caspases Assay Kit (Molecular Probes). The kit employs a fluorescently labeled inhibitor of caspases reagent containing a fluoromethyl ketone group, a caspase specific recognition sequence (VAD), and a carboxyfluorescein (FAM) group as a reporter. Cryopreserved PBMCs were thawed, washed, and resuspended at 1 × 106 cells per milliliter in 300 μL RPMI media with 10% fetal bovine syndrome. After adding 10 μL of 30× fluorescently labeled inhibitor of caspases working solution to each culture, the suspensions were incubated for 1 hour at 37°C and 5% CO2. The cells were washed twice with 1× wash buffer supplied by the manufacturer before proceeding with subsequent surface staining. Apoptosis was analyzed based on caspase-positive and caspase-negative populations, with gating based on a fluorescence minus one control.
Immune Activation and Functional Immunophenotype
Activated T cells were measured as previously described.9 Further immunophenotyping was performed on cryopreserved PBMCs, which were thawed and subsequently stained with antibody panels for activation and PD-1. For activation panels, cells were stained with the following antibodies: HLADR FITC, CD38 PE, CD3 PerCp Cy5.5, CD4 APC CY7, CD27 APC, CD45RA PECy7, and CD8 Pacific Blue (BD BioSciences, San Jose, CA). For the PD-1 panels, cells were stained with antibodies including CD3 PerCP Cy5.5, CD4 PeCy7, CD8 Pacific Blue, HLADR FITC, CD38 PE, and PD-1 APC (BD BioSciences). Data were collected on an 8-color flow cytometer (LSRII; BD Biosciences) and analyzed using FLOWJO software (TreeStar, San Carlos, CA). A minimum of 30,000 CD4+ cells per sample was acquired on the LSRII. Dead cells were first gated out using a violet excited viability dye (LIVE/DEAD Fixable Dead Cell Stain; Invitrogen). Immune activation was defined as the percent of CD38+ HLADR+ T cells. PD-1 level was defined as the percent expression of PD-1 APC on CD3+ CD8+ T cells. Gating was standardized and set using fluorescence controls for HLADR, CD38, and PD-1.
Groups were compared using the Mann-Whitney U test or the paired t test using PRISM software version 4.02 (GraphPad, San Diego, CA). Statistical significance was defined as P < 0.05.
We analyzed subtype distribution in our study population based on the Pol region of the genome, and valid data were obtained for 172 samples. We found that subtype distribution in our study population (Fig. 1) is composed primarily of subtypes A and D (n = 84 and 76, respectively). No correlation between viral subtypes (A and D) for CD4 count (mean values 95 and 70 count/mL; P > 0.05; subtype A and D, respectively) or viral load (mean values 203, 000 and 151,000 copies/mL; P > 0.05; subtype A and D, respectively) was observed before ART initiation (Table 1). In addition, CD4 cell gain after ART suppression did not differ significantly between the 2 infecting subtypes within 6 months (Fig. 1C). There was no significant difference in subtype distribution by sex or age (P > 0.05; data not shown).
CD4 Immune Activation Decreases Post ART Suppression in Subtypes A and D
Different HIV-1 subtypes may vary in pathogenesis, resulting in distinct profiles of immune activation. Others and we have described heightened immune activation in HIV-infected individuals from Africa compared with those from Europe and the United States.9,12 Activation staining was performed as previously described.9,13 CD8 and CD4 activation was defined as the percentage of CD3+ CD8+ CD38+ HLADR+ or CD3+ CD4+ CD38+ HLADR+ lymphocytes, respectively. Both CD8 and CD4 T-cell immune activation were examined separately at baseline (when the patients were naive) and again at 6 months after the initiation of antiretroviral treatment. Because the majority of our population was infected with subtypes A and D, we focused our immune activation analysis on these 2 subtypes. We observed no significant differences in CD4 and CD8 immune activation between these subtypes (Fig. 2; data not shown).
Differential Levels of Apoptosis in Activated Cells Between Subtypes A and D
We next examined the level of apoptosis in CD4+ T cells between the 2 subgroups. Overall levels of apoptosis were highest in the activated CD4 cells compared with the total fraction of CD4+ caspase+ T cells and significantly decreased with viral suppression (Fig. 3A; P < 0.0001). Interestingly, the apoptosis of activated CD4 cells in individuals infected with subtype D was significantly higher compared with those infected with subtype A (Fig. 3B; P = 0.028) before antiretroviral treatment. After ART-mediated viral suppression, we observed normalization of activation to similar levels between subtypes.
PD-1 Expression on CD4+ T Cells
The inhibitory programmed cell death receptor (PD-1) has been compared with activation marker CD38 and viral load as a predictor for clinical progression. PD-1 is upregulated in chronic HIV infection, and its expression correlates positively with plasma viral load and inversely with CD4+ T-cell count. We found that levels of expression of PD-1 on CD4 cells in subtype D was substantially higher compared with that in subtype A (Fig. 4A; P = 0.01). This difference was not observed in the CD8 population (Fig. 4B; P = 0.97). The level of PD-1 expression in the 2 populations was not significantly different after antiretroviral suppression (P = 0.25; data not shown).
The mechanism by which HIV causes immune destruction is linked to its ability to induce a generalized immune hyperactivation. Discordant responses to ART have been linked to the level of cellular activation.14-16 How chronic activation might be detrimental to the immune system remains unclear. Bystander activation of uninfected CD4+ T cells has been demonstrated to increase susceptibility to infection and subsequent virus production ex vivo. T-cell apoptosis and subsequent immune exhaustion are likely key factors in the eventual failure of viral control.
HIV-1 subtypes may confer distinct pathogenesis and impact HIV disease progression. Subtypes A and D account for the majority of infection in our treatment-naive study population in Uganda. CD4+ T-cell immune activation significantly decreased after ART-mediated viral suppression as we have previously reported.17 Although subtypes did not correlate with generalized levels of immune activation, we observed significant differences in CD4 dysfunction in individuals infected with subtype D, as demonstrated by higher level of apoptosis and PD-1 expression. These data support the hypothesis that subtype D is more pathogenic14,15 and is consistent with previous cohort studies demonstrating faster disease progression in subtype D that is independent of viral load levels.1
The role of HIV subtype and viral gene products may be critical in determining the level of immunopathogenesis associated with HIV disease progression to AIDS. We propose that the differential subtype-induced activation and subsequent apoptosis is one such mechanism that leads to differential clinical disease outcome in Uganda.1 The difference in the level of activation-associated apoptosis between subtypes A and D becomes insignificant after 6 months of ART. This finding may reflect on the specific subtype's ability to induce the expression of apoptosis ligands and disrupt the effective generation of T-cell immunity. However, the full explorations of all mechanisms involved in treatment failure and immune recovery cannot be assessed in this relatively short follow-up, and the small sample size of our study limits definitive long-term outcome. The true clinical impact of T-cell dysfunction in association with HIV subtypes in predicting disease outcome will require a larger longitudinal cohort study. The recognition of the different HIV-1 subtypes has led many to question whether properties of HIV-1 infection and its consequences as a whole can be generalized among different subtypes. Our findings suggest that infection with one subtype may be more aggressive than others with regard to disease progression. Such diversity could potentially affect the overall efficacy of HIV therapy or intervention strategies in the affected population.
1. Kiwanuka N, Laeyendecker O, Robb M, et al. Effect of human immunodeficiency virus type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis
2. Kaleebu P, French N, Mahe C, et al. Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J Infec Dis
3. Kaleebu P, Ross A, Morgan D, et al. Relationship between HIV-1 env subtypes A and D and disease progression in a rural Ugandan cohort. AIDS
4. Baeten JM, Chohan B, Lavreys L, et al. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis
5. Church JD, Huang W, Mwatha A, et al. HIV-1 tropism and survival in vertically infected Ugandan infants. J Infect Dis
6. Kaleebu P, Nankya IL, Yirrell DL, et al. Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan cohort. J Acquir Immune Defic Syndr
7. Haase AT. Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Annu Rev Immunol
8. Hazenberg MD, Stuart JW, Otto SA, et al. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood
9. Eggena MP, Barugahare B, Okello M, et al. T cell activation in HIV-seropositive Ugandans: differential associations with viral load, CD4+ T cell depletion, and coinfection. J Infect Dis
10. Baker CA, Bousheri S, Ssewanyana I, et al. HIV subtypes distribution and implication for antiretroviral treatment in a Ugandan population. J Int Assoc Physicians AIDS Care (Chic Ill)
11. Tam LW, Chui CK, Brumme CJ, et al. The relationship between resistance and adherence in drug-naive individuals initiating HAART is specific to individual drug classes. J Acquir Immune Defic Syndr
12. Rizzardini G, Piconi S, Ruzzante S, et al. Immunological activation markers in the serum of African and European HIV-seropositive and seronegative individuals. AIDS
13. Eggena MP, Barugahare B, Jones N, et al. Depletion of regulatory T Cells in HIV infection is associated with immune activation. J Immunol
14. Katzenstein TL. Molecular biological assessment methods and understanding the course of the HIV infection. APMIS Suppl
15. Hazenberg MD, Otto SA, Wit FW, et al. Discordant responses during antiretroviral therapy: role of immune activation and T cell redistribution rather than true CD4 T cell loss. AIDS
16. Sufka S, Ferrari G, Gryszowka V, et al. Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control. J Infec Dis
17. Baker CA, Emenyonu N, Ssewanyana I, et al. Profile of immunologic recovery in HIV-infected Ugandan adults after antiretroviral therapy. AIDS Res Hum Retroviruses
© 2009 Lippincott Williams & Wilkins, Inc.